Get marketing news you'll actually want to read
Marketing Brew informs marketing pros of the latest on brand strategy, social media, and ad tech via our weekday newsletter, virtual events, marketing conferences, and digital guides.
After gaining full US FDA approval this week, Pfizer can now market its Covid vaccine by a brand name: Comirnaty, a combo of the words community, immunity, mRNA, and Covid.
- If you’re a marketer from Brand Institute—the naming company that coined Pfizer’s official vaccine name—this isn’t news to you.
- “Over 1,000 names were created to ultimately arrive at Comirnaty,” Scott Piergrossi, president, creative at Brand Institute, told Marketing Brew.
- Brand Institute also helped Moderna choose its vaccine’s official name (spoiler alert: it’s Spikevax), per Newsweek.
Big picture: As The Washington Post noted, Comirnaty was roasted online. So we spoke with Laurel Sutton, president of the American Name Society and cofounder of naming agency Catchword, to get an expert’s opinion on the new moniker.
The verdict? She’s just not that into it. Sutton told us Comirnaty is “quite difficult to pronounce,” calling it a “naming company name,” aka one that was “obviously coined...in order to fulfill the requirements for legal availability and FDA requirements for drug names, which are quite strict.”
It gets worse: She doesn’t think the name will stick. “People will just keep calling it the Pfizer vaccine (as opposed to Moderna or J&J). Moderna’s name (Spikevax) is objectively better, but I’d bet people will keep calling it Moderna.”
An alternative: Sutton preferred the name Covuity, one of the other names being considered for the vaccine. “It’s a lot easier to spell and pronounce, but it likely didn’t satisfy their desire to smash a bunch of words together so they could cram every marketing message into nine letters.”
Bottom line: “As we often remind our clients: The name doesn’t have to carry every message! That’s what marketing is for,” Sutton concluded.—PB